FDA-approved Skin & aging

Afamelanotide

Afamelanotide is a MC1R agonist. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Afamelanotide has an FDA-approved product on the U.S. market, marketed as Scenesse under application NDA210797.

The current label is held by Clinuvel Inc.

From the FDA label

What Afamelanotide is approved to treat

SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

3 sources on Afamelanotide published between 2015 and 2023, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on skin & aging

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Afamelanotide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides